| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 120 | 2025 | 615 | 15.840 |
Why?
|
| Colonoscopy | 82 | 2025 | 253 | 9.320 |
Why?
|
| Early Detection of Cancer | 58 | 2024 | 513 | 8.120 |
Why?
|
| Occult Blood | 36 | 2024 | 154 | 5.600 |
Why?
|
| Mass Screening | 48 | 2024 | 677 | 4.460 |
Why?
|
| Adenoma | 24 | 2024 | 93 | 3.490 |
Why?
|
| Feces | 21 | 2024 | 80 | 2.970 |
Why?
|
| Sigmoidoscopy | 26 | 2020 | 65 | 2.710 |
Why?
|
| Humans | 191 | 2025 | 17762 | 2.500 |
Why?
|
| Hemoglobins | 7 | 2018 | 39 | 2.060 |
Why?
|
| Colonic Neoplasms | 15 | 2017 | 156 | 1.970 |
Why?
|
| Male | 110 | 2024 | 10106 | 1.770 |
Why?
|
| Adenocarcinoma | 16 | 2018 | 172 | 1.770 |
Why?
|
| Middle Aged | 100 | 2024 | 7988 | 1.720 |
Why?
|
| Aged | 92 | 2024 | 6150 | 1.720 |
Why?
|
| Female | 109 | 2024 | 12740 | 1.590 |
Why?
|
| Barrett Esophagus | 14 | 2013 | 114 | 1.460 |
Why?
|
| Esophageal Neoplasms | 11 | 2013 | 115 | 1.380 |
Why?
|
| African Americans | 3 | 2022 | 472 | 1.340 |
Why?
|
| Colonic Polyps | 11 | 2025 | 35 | 1.290 |
Why?
|
| Immunologic Tests | 2 | 2020 | 6 | 1.250 |
Why?
|
| California | 34 | 2024 | 2326 | 1.150 |
Why?
|
| Healthcare Disparities | 4 | 2022 | 203 | 1.070 |
Why?
|
| Risk Factors | 46 | 2024 | 3356 | 1.030 |
Why?
|
| Immunochemistry | 10 | 2017 | 18 | 1.020 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 143 | 1.000 |
Why?
|
| Specimen Handling | 3 | 2016 | 20 | 0.970 |
Why?
|
| Gastroesophageal Reflux | 14 | 2008 | 79 | 0.940 |
Why?
|
| Population Surveillance | 10 | 2017 | 264 | 0.910 |
Why?
|
| Immunohistochemistry | 6 | 2019 | 44 | 0.900 |
Why?
|
| Sensitivity and Specificity | 21 | 2018 | 304 | 0.870 |
Why?
|
| Gastroenterologists | 3 | 2017 | 7 | 0.840 |
Why?
|
| Aged, 80 and over | 33 | 2024 | 1923 | 0.820 |
Why?
|
| Adenomatous Polyps | 6 | 2016 | 15 | 0.790 |
Why?
|
| Intestinal Polyps | 3 | 2012 | 7 | 0.760 |
Why?
|
| Goals | 1 | 2021 | 30 | 0.740 |
Why?
|
| Racism | 1 | 2021 | 19 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2020 | 4 | 0.710 |
Why?
|
| Retrospective Studies | 25 | 2024 | 2461 | 0.710 |
Why?
|
| Gastroenterology | 5 | 2025 | 19 | 0.700 |
Why?
|
| Incidence | 19 | 2024 | 1266 | 0.700 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 107 | 0.690 |
Why?
|
| Postal Service | 3 | 2020 | 73 | 0.690 |
Why?
|
| Esophagoscopy | 4 | 2013 | 19 | 0.660 |
Why?
|
| Education, Medical, Continuing | 3 | 2017 | 30 | 0.650 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 7 | 2019 | 15 | 0.620 |
Why?
|
| Precancerous Conditions | 7 | 2020 | 47 | 0.620 |
Why?
|
| Predictive Value of Tests | 14 | 2025 | 354 | 0.600 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 292 | 0.600 |
Why?
|
| Case-Control Studies | 29 | 2024 | 1120 | 0.600 |
Why?
|
| United States | 30 | 2025 | 4003 | 0.590 |
Why?
|
| Bone Morphogenetic Protein 3 | 2 | 2017 | 3 | 0.590 |
Why?
|
| Muscle Proteins | 2 | 2017 | 5 | 0.590 |
Why?
|
| Time Factors | 19 | 2020 | 1093 | 0.580 |
Why?
|
| Stomach Neoplasms | 4 | 2008 | 41 | 0.580 |
Why?
|
| Pathologists | 1 | 2017 | 15 | 0.580 |
Why?
|
| Nerve Tissue Proteins | 2 | 2017 | 22 | 0.580 |
Why?
|
| Neoplastic Syndromes, Hereditary | 4 | 2017 | 5 | 0.570 |
Why?
|
| Brain Neoplasms | 4 | 2017 | 15 | 0.560 |
Why?
|
| Genes, ras | 1 | 2017 | 5 | 0.560 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2016 | 20 | 0.560 |
Why?
|
| Risk Assessment | 17 | 2020 | 1101 | 0.550 |
Why?
|
| Colon | 7 | 2020 | 20 | 0.540 |
Why?
|
| Program Development | 1 | 2017 | 69 | 0.540 |
Why?
|
| Cohort Studies | 17 | 2024 | 2586 | 0.540 |
Why?
|
| Research | 1 | 2017 | 65 | 0.540 |
Why?
|
| Adult | 47 | 2024 | 7678 | 0.540 |
Why?
|
| Age Factors | 14 | 2020 | 918 | 0.530 |
Why?
|
| Health Maintenance Organizations | 8 | 2011 | 417 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2016 | 246 | 0.500 |
Why?
|
| Peptic Ulcer | 6 | 2003 | 14 | 0.490 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2009 | 20 | 0.490 |
Why?
|
| Preventive Health Services | 1 | 2016 | 160 | 0.480 |
Why?
|
| Rectal Neoplasms | 5 | 2016 | 65 | 0.480 |
Why?
|
| Patient Compliance | 3 | 2016 | 300 | 0.480 |
Why?
|
| Esophagus | 2 | 2013 | 12 | 0.470 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2011 | 7 | 0.470 |
Why?
|
| Obesity | 7 | 2008 | 842 | 0.440 |
Why?
|
| Health Promotion | 3 | 2013 | 281 | 0.430 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 17 | 0.430 |
Why?
|
| Catheter Ablation | 1 | 2013 | 11 | 0.430 |
Why?
|
| Reminder Systems | 2 | 2020 | 80 | 0.420 |
Why?
|
| Helicobacter Infections | 5 | 2008 | 22 | 0.400 |
Why?
|
| Helicobacter pylori | 5 | 2008 | 24 | 0.400 |
Why?
|
| DNA, Neoplasm | 7 | 2016 | 20 | 0.390 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2015 | 535 | 0.380 |
Why?
|
| Evidence-Based Medicine | 6 | 2025 | 186 | 0.370 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 40 | 0.360 |
Why?
|
| Cathartics | 3 | 2014 | 3 | 0.360 |
Why?
|
| Genetic Testing | 6 | 2017 | 71 | 0.340 |
Why?
|
| Intestinal Perforation | 3 | 2006 | 8 | 0.340 |
Why?
|
| DNA Methylation | 4 | 2017 | 41 | 0.340 |
Why?
|
| Mutation | 6 | 2017 | 130 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 321 | 0.320 |
Why?
|
| Quality Indicators, Health Care | 2 | 2024 | 181 | 0.320 |
Why?
|
| Prospective Studies | 6 | 2020 | 1279 | 0.310 |
Why?
|
| Prevalence | 8 | 2024 | 886 | 0.290 |
Why?
|
| Odds Ratio | 8 | 2018 | 671 | 0.290 |
Why?
|
| Sigmoid Neoplasms | 2 | 2005 | 2 | 0.290 |
Why?
|
| Endoscopy | 2 | 2023 | 10 | 0.280 |
Why?
|
| Carcinoma | 2 | 2017 | 22 | 0.280 |
Why?
|
| Diet | 6 | 2008 | 365 | 0.270 |
Why?
|
| Therapeutic Irrigation | 3 | 2014 | 4 | 0.270 |
Why?
|
| Cardia | 2 | 2008 | 15 | 0.270 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2009 | 65 | 0.260 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2014 | 18 | 0.260 |
Why?
|
| Disease Progression | 3 | 2017 | 264 | 0.250 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2025 | 7 | 0.250 |
Why?
|
| Sex Factors | 7 | 2012 | 644 | 0.250 |
Why?
|
| Societies, Medical | 7 | 2025 | 75 | 0.250 |
Why?
|
| Health Care Costs | 3 | 2015 | 229 | 0.240 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 327 | 0.240 |
Why?
|
| Immunoassay | 2 | 2016 | 8 | 0.240 |
Why?
|
| Genetic Therapy | 2 | 2014 | 8 | 0.230 |
Why?
|
| Colonography, Computed Tomographic | 6 | 2017 | 10 | 0.230 |
Why?
|
| Prognosis | 6 | 2024 | 609 | 0.230 |
Why?
|
| Consensus | 7 | 2017 | 41 | 0.230 |
Why?
|
| Algorithms | 5 | 2020 | 239 | 0.230 |
Why?
|
| Forecasting | 3 | 2023 | 75 | 0.230 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 26 | 0.230 |
Why?
|
| Logistic Models | 10 | 2018 | 927 | 0.230 |
Why?
|
| Health Services Needs and Demand | 1 | 2004 | 93 | 0.230 |
Why?
|
| Histamine H2 Antagonists | 2 | 2010 | 13 | 0.230 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2023 | 8 | 0.220 |
Why?
|
| Colectomy | 5 | 2016 | 27 | 0.220 |
Why?
|
| Quality Improvement | 2 | 2015 | 194 | 0.220 |
Why?
|
| Myocardial Infarction | 2 | 2002 | 238 | 0.210 |
Why?
|
| Polymorphism, Genetic | 4 | 2007 | 62 | 0.210 |
Why?
|
| Body Mass Index | 8 | 2011 | 964 | 0.210 |
Why?
|
| Anti-Ulcer Agents | 2 | 2003 | 5 | 0.210 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 27 | 0.210 |
Why?
|
| DNA Mismatch Repair | 2 | 2019 | 5 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 5 | 2015 | 250 | 0.200 |
Why?
|
| Neoplasms | 3 | 2015 | 444 | 0.200 |
Why?
|
| Dyspepsia | 2 | 2001 | 5 | 0.200 |
Why?
|
| Health Behavior | 1 | 2004 | 360 | 0.190 |
Why?
|
| DNA Mutational Analysis | 6 | 2014 | 19 | 0.180 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 93 | 0.180 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 1330 | 0.180 |
Why?
|
| Urologic Neoplasms | 2 | 2017 | 7 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2014 | 375 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2022 | 146 | 0.180 |
Why?
|
| Laboratories | 1 | 2020 | 18 | 0.170 |
Why?
|
| Endometrial Neoplasms | 2 | 2017 | 35 | 0.170 |
Why?
|
| Aftercare | 2 | 2017 | 49 | 0.170 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 24 | 0.170 |
Why?
|
| Health Equity | 1 | 2020 | 22 | 0.170 |
Why?
|
| Disease Management | 2 | 2016 | 135 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2020 | 218 | 0.170 |
Why?
|
| Fatigue | 2 | 2016 | 34 | 0.170 |
Why?
|
| Hip Fractures | 1 | 2010 | 67 | 0.170 |
Why?
|
| Risk | 4 | 2015 | 517 | 0.160 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 1999 | 1 | 0.160 |
Why?
|
| Angina, Unstable | 1 | 1999 | 7 | 0.160 |
Why?
|
| Peptides | 1 | 1999 | 12 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 29 | 0.160 |
Why?
|
| Genetic Markers | 2 | 2017 | 25 | 0.160 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1999 | 24 | 0.160 |
Why?
|
| CpG Islands | 3 | 2007 | 22 | 0.160 |
Why?
|
| Adenomatous Polyposis Coli | 3 | 2008 | 4 | 0.160 |
Why?
|
| Quality of Life | 3 | 2009 | 510 | 0.160 |
Why?
|
| Omeprazole | 1 | 1998 | 2 | 0.150 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 1998 | 12 | 0.150 |
Why?
|
| Area Under Curve | 1 | 2018 | 34 | 0.150 |
Why?
|
| ROC Curve | 1 | 2018 | 77 | 0.150 |
Why?
|
| Program Evaluation | 2 | 2016 | 223 | 0.150 |
Why?
|
| Utah | 7 | 2007 | 33 | 0.150 |
Why?
|
| Adolescent | 11 | 2012 | 3685 | 0.150 |
Why?
|
| Gastritis | 1 | 1997 | 2 | 0.150 |
Why?
|
| Advisory Committees | 5 | 2016 | 113 | 0.150 |
Why?
|
| Survival Analysis | 3 | 2016 | 215 | 0.140 |
Why?
|
| Treatment Outcome | 7 | 2016 | 1260 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2010 | 755 | 0.140 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 60 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 390 | 0.140 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 29 | 0.140 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 710 | 0.140 |
Why?
|
| False Positive Reactions | 1 | 2016 | 26 | 0.140 |
Why?
|
| Temperature | 1 | 2016 | 19 | 0.140 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 34 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 2 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 4 | 0.140 |
Why?
|
| Community Health Centers | 1 | 2017 | 64 | 0.140 |
Why?
|
| Depression | 3 | 2011 | 505 | 0.140 |
Why?
|
| Population Health | 1 | 2016 | 5 | 0.130 |
Why?
|
| Sex Distribution | 3 | 2004 | 190 | 0.130 |
Why?
|
| Aspirin | 3 | 2006 | 63 | 0.130 |
Why?
|
| Seasons | 1 | 2016 | 105 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2007 | 15 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2009 | 127 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 599 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 1213 | 0.130 |
Why?
|
| Community-Institutional Relations | 2 | 2015 | 43 | 0.130 |
Why?
|
| Smoking | 4 | 2008 | 483 | 0.130 |
Why?
|
| Community Health Services | 1 | 2016 | 83 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2015 | 315 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 381 | 0.130 |
Why?
|
| Microsatellite Repeats | 4 | 2005 | 10 | 0.130 |
Why?
|
| Nurses | 1 | 2015 | 36 | 0.130 |
Why?
|
| Hypoglycemic Agents | 2 | 2008 | 271 | 0.130 |
Why?
|
| Models, Statistical | 2 | 2015 | 178 | 0.120 |
Why?
|
| Patient Participation | 1 | 2016 | 134 | 0.120 |
Why?
|
| Quality of Health Care | 2 | 2016 | 326 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 7 | 0.120 |
Why?
|
| Mandibular Diseases | 1 | 1995 | 1 | 0.120 |
Why?
|
| Process Assessment (Health Care) | 1 | 2015 | 24 | 0.120 |
Why?
|
| Asthma | 1 | 1998 | 385 | 0.120 |
Why?
|
| Colonic Diseases | 1 | 2015 | 3 | 0.120 |
Why?
|
| Cytokines | 1 | 2015 | 30 | 0.120 |
Why?
|
| Biopsy | 3 | 2009 | 75 | 0.120 |
Why?
|
| Alleles | 4 | 2017 | 85 | 0.120 |
Why?
|
| Defecation | 1 | 2014 | 5 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 8 | 0.120 |
Why?
|
| Data Collection | 1 | 2015 | 256 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 88 | 0.110 |
Why?
|
| Radio Waves | 1 | 2003 | 2 | 0.110 |
Why?
|
| Guaiac | 2 | 2017 | 3 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 2 | 2007 | 169 | 0.110 |
Why?
|
| Bias | 4 | 2017 | 102 | 0.110 |
Why?
|
| Health Services Research | 1 | 2014 | 231 | 0.110 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2013 | 2 | 0.110 |
Why?
|
| Insurance Benefits | 1 | 2013 | 14 | 0.110 |
Why?
|
| Heterosexuality | 1 | 2013 | 9 | 0.110 |
Why?
|
| Young Adult | 8 | 2013 | 2461 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2013 | 52 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 197 | 0.100 |
Why?
|
| Medicaid | 2 | 2024 | 190 | 0.100 |
Why?
|
| Diagnostic Errors | 2 | 2009 | 28 | 0.100 |
Why?
|
| Genotype | 6 | 2013 | 227 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 65 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 17 | 0.100 |
Why?
|
| Continental Population Groups | 4 | 2017 | 302 | 0.100 |
Why?
|
| Iron | 2 | 2008 | 16 | 0.100 |
Why?
|
| Survival Rate | 4 | 2012 | 260 | 0.100 |
Why?
|
| Colorado | 1 | 2012 | 164 | 0.100 |
Why?
|
| Anxiety | 2 | 2011 | 151 | 0.100 |
Why?
|
| Surveys and Questionnaires | 8 | 2008 | 1321 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2002 | 29 | 0.100 |
Why?
|
| Ontario | 1 | 2011 | 16 | 0.090 |
Why?
|
| United Kingdom | 1 | 2011 | 30 | 0.090 |
Why?
|
| Telephone | 1 | 2012 | 161 | 0.090 |
Why?
|
| Alcohol Drinking | 4 | 2008 | 373 | 0.090 |
Why?
|
| Thiazolidinediones | 2 | 2008 | 52 | 0.090 |
Why?
|
| Poisson Distribution | 2 | 2012 | 88 | 0.090 |
Why?
|
| Enema | 3 | 2014 | 3 | 0.090 |
Why?
|
| Confidence Intervals | 3 | 2008 | 237 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2008 | 39 | 0.090 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2011 | 128 | 0.090 |
Why?
|
| Pedigree | 3 | 2014 | 60 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2011 | 134 | 0.090 |
Why?
|
| Medical History Taking | 2 | 2020 | 35 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2009 | 155 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2013 | 265 | 0.080 |
Why?
|
| Citalopram | 1 | 2009 | 14 | 0.080 |
Why?
|
| Chronic Pain | 1 | 2011 | 127 | 0.080 |
Why?
|
| Ibuprofen | 2 | 2006 | 9 | 0.080 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2009 | 28 | 0.080 |
Why?
|
| Glycated Hemoglobin A | 1 | 2010 | 216 | 0.080 |
Why?
|
| Comorbidity | 1 | 2011 | 597 | 0.080 |
Why?
|
| Life Style | 3 | 2008 | 333 | 0.080 |
Why?
|
| Ethnic Groups | 4 | 2017 | 485 | 0.080 |
Why?
|
| Genetic Variation | 2 | 2006 | 80 | 0.080 |
Why?
|
| Postoperative Care | 2 | 2006 | 20 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2007 | 213 | 0.080 |
Why?
|
| Early Diagnosis | 2 | 2008 | 38 | 0.080 |
Why?
|
| Beer | 1 | 2008 | 9 | 0.080 |
Why?
|
| Ferritins | 1 | 2008 | 9 | 0.080 |
Why?
|
| Wine | 1 | 2008 | 18 | 0.080 |
Why?
|
| Cause of Death | 2 | 2020 | 181 | 0.080 |
Why?
|
| Hemochromatosis | 1 | 2008 | 7 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 7 | 0.080 |
Why?
|
| Antioxidants | 1 | 2008 | 40 | 0.080 |
Why?
|
| Fruit | 1 | 2008 | 79 | 0.080 |
Why?
|
| Vegetables | 1 | 2008 | 87 | 0.080 |
Why?
|
| Liver Diseases | 2 | 2008 | 23 | 0.080 |
Why?
|
| Lovastatin | 1 | 2008 | 7 | 0.070 |
Why?
|
| Liver | 1 | 2008 | 32 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 10 | 0.070 |
Why?
|
| Germ-Line Mutation | 3 | 2002 | 18 | 0.070 |
Why?
|
| Abdomen | 2 | 2008 | 20 | 0.070 |
Why?
|
| DNA | 2 | 2017 | 22 | 0.070 |
Why?
|
| Abdominal Fat | 1 | 2007 | 14 | 0.070 |
Why?
|
| Information Systems | 1 | 2007 | 22 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 568 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 121 | 0.070 |
Why?
|
| Postoperative Hemorrhage | 1 | 2006 | 8 | 0.070 |
Why?
|
| Body Size | 1 | 2007 | 31 | 0.070 |
Why?
|
| Diverticulitis, Colonic | 1 | 2006 | 8 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2005 | 300 | 0.070 |
Why?
|
| Glucuronosyltransferase | 1 | 2006 | 1 | 0.070 |
Why?
|
| Heterozygote | 2 | 2008 | 26 | 0.070 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2006 | 6 | 0.070 |
Why?
|
| Chlorophyll | 1 | 2006 | 1 | 0.070 |
Why?
|
| Lichens | 1 | 2006 | 1 | 0.070 |
Why?
|
| Sulfur | 1 | 2006 | 1 | 0.070 |
Why?
|
| Acid Rain | 1 | 2006 | 1 | 0.070 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2006 | 4 | 0.070 |
Why?
|
| Copper | 1 | 2006 | 4 | 0.070 |
Why?
|
| Ultraviolet Rays | 1 | 2006 | 6 | 0.070 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2006 | 3 | 0.070 |
Why?
|
| Endosonography | 2 | 2016 | 9 | 0.070 |
Why?
|
| Monitoring, Physiologic | 3 | 2016 | 40 | 0.070 |
Why?
|
| Workload | 2 | 2016 | 30 | 0.060 |
Why?
|
| Genetic Counseling | 2 | 2017 | 26 | 0.060 |
Why?
|
| Dinucleoside Phosphates | 1 | 2005 | 2 | 0.060 |
Why?
|
| Air Pollutants | 1 | 2006 | 52 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 172 | 0.060 |
Why?
|
| Colorectal Surgery | 1 | 2005 | 2 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 2005 | 7 | 0.060 |
Why?
|
| Informed Consent | 1 | 2005 | 19 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 35 | 0.060 |
Why?
|
| Apolipoproteins E | 1 | 2005 | 10 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2005 | 14 | 0.060 |
Why?
|
| Age Distribution | 2 | 2006 | 246 | 0.060 |
Why?
|
| Barium Sulfate | 2 | 2008 | 2 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2006 | 102 | 0.060 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2004 | 6 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 21 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2007 | 154 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2002 | 132 | 0.060 |
Why?
|
| Placebos | 2 | 2009 | 21 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2024 | 6 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2014 | 85 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 98 | 0.060 |
Why?
|
| Receptor, Insulin | 1 | 2004 | 6 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 212 | 0.060 |
Why?
|
| Confounding Factors (Epidemiology) | 2 | 2008 | 86 | 0.060 |
Why?
|
| Coronary Disease | 2 | 2008 | 183 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2003 | 12 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2005 | 169 | 0.060 |
Why?
|
| Indicators and Reagents | 2 | 2017 | 5 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 719 | 0.050 |
Why?
|
| European Continental Ancestry Group | 2 | 2006 | 529 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2014 | 32 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2002 | 29 | 0.050 |
Why?
|
| Medicare | 1 | 1984 | 205 | 0.050 |
Why?
|
| Duodenal Ulcer | 1 | 2002 | 2 | 0.050 |
Why?
|
| Duodenal Diseases | 1 | 2002 | 3 | 0.050 |
Why?
|
| Stomach Ulcer | 1 | 2002 | 3 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2008 | 769 | 0.050 |
Why?
|
| Total Quality Management | 1 | 2002 | 24 | 0.050 |
Why?
|
| Alendronate | 1 | 2002 | 15 | 0.050 |
Why?
|
| American Cancer Society | 3 | 2006 | 12 | 0.050 |
Why?
|
| Reference Values | 2 | 2016 | 92 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2004 | 331 | 0.050 |
Why?
|
| Costs and Cost Analysis | 2 | 2000 | 80 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2002 | 85 | 0.050 |
Why?
|
| Phenotype | 3 | 2007 | 151 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2001 | 38 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2020 | 13 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 287 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 6 | 0.040 |
Why?
|
| Gastric Acid | 1 | 2010 | 4 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 36 | 0.040 |
Why?
|
| Absenteeism | 1 | 2000 | 24 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2000 | 3 | 0.040 |
Why?
|
| Stents | 1 | 2000 | 11 | 0.040 |
Why?
|
| Demography | 1 | 2020 | 101 | 0.040 |
Why?
|
| SEER Program | 2 | 2004 | 91 | 0.040 |
Why?
|
| Chest Pain | 1 | 1999 | 14 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2000 | 46 | 0.040 |
Why?
|
| Registries | 3 | 2012 | 472 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 129 | 0.040 |
Why?
|
| Contrast Media | 1 | 1999 | 9 | 0.040 |
Why?
|
| Hospitalization | 2 | 2002 | 808 | 0.040 |
Why?
|
| Heart Diseases | 1 | 1999 | 77 | 0.040 |
Why?
|
| Systematized Nomenclature of Medicine | 1 | 2009 | 5 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 1999 | 1 | 0.040 |
Why?
|
| Metaplasia | 1 | 2009 | 7 | 0.040 |
Why?
|
| Isoenzymes | 1 | 1999 | 4 | 0.040 |
Why?
|
| Observer Variation | 1 | 2009 | 37 | 0.040 |
Why?
|
| Medical Audit | 1 | 2009 | 38 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 19 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 32 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 212 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 1998 | 17 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 46 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 85 | 0.040 |
Why?
|
| Emotions | 1 | 1998 | 34 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 1998 | 69 | 0.040 |
Why?
|
| Drug Costs | 1 | 1998 | 34 | 0.040 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2008 | 9 | 0.040 |
Why?
|
| Mortality | 1 | 1999 | 118 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 1998 | 85 | 0.040 |
Why?
|
| Patient Navigation | 1 | 2017 | 15 | 0.040 |
Why?
|
| Capsule Endoscopy | 1 | 2017 | 1 | 0.040 |
Why?
|
| Septins | 1 | 2017 | 2 | 0.040 |
Why?
|
| Duodenal Neoplasms | 1 | 2017 | 1 | 0.040 |
Why?
|
| Ileal Neoplasms | 1 | 2017 | 1 | 0.040 |
Why?
|
| Jejunal Neoplasms | 1 | 2017 | 1 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 55 | 0.040 |
Why?
|
| Lymphoma | 1 | 2017 | 6 | 0.040 |
Why?
|
| Leukemia | 1 | 2017 | 9 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2016 | 2 | 0.030 |
Why?
|
| Colon, Ascending | 1 | 2016 | 2 | 0.030 |
Why?
|
| Colon, Descending | 1 | 2016 | 2 | 0.030 |
Why?
|
| Colon, Transverse | 1 | 2016 | 2 | 0.030 |
Why?
|
| Minnesota | 2 | 2007 | 53 | 0.030 |
Why?
|
| Anthropometry | 1 | 2006 | 66 | 0.030 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 26 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 1999 | 368 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 106 | 0.030 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2006 | 90 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 5 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1998 | 247 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 16 | 0.030 |
Why?
|
| Health Status | 1 | 1998 | 298 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2008 | 305 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 57 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 82 | 0.030 |
Why?
|
| Insulin | 2 | 2007 | 206 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2006 | 162 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2015 | 3 | 0.030 |
Why?
|
| Attention | 1 | 2015 | 10 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 11 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 20 | 0.030 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 1 | 2015 | 32 | 0.030 |
Why?
|
| Mandible | 1 | 1995 | 2 | 0.030 |
Why?
|
| Israel | 1 | 1995 | 2 | 0.030 |
Why?
|
| Radiography, Panoramic | 1 | 1995 | 2 | 0.030 |
Why?
|
| Bone Resorption | 1 | 1995 | 4 | 0.030 |
Why?
|
| Focus Groups | 1 | 2015 | 147 | 0.030 |
Why?
|
| Social Environment | 1 | 2015 | 88 | 0.030 |
Why?
|
| Streptococcus bovis | 1 | 1994 | 1 | 0.030 |
Why?
|
| Peritonitis | 1 | 1994 | 2 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2015 | 99 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 44 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 91 | 0.030 |
Why?
|
| Quality Control | 1 | 2014 | 45 | 0.030 |
Why?
|
| Streptococcal Infections | 1 | 1994 | 22 | 0.030 |
Why?
|
| Motivation | 1 | 2015 | 131 | 0.030 |
Why?
|
| Public Health | 1 | 2015 | 81 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2015 | 113 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 2014 | 1 | 0.030 |
Why?
|
| Actins | 1 | 2014 | 2 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 7 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 21 | 0.030 |
Why?
|
| ras Proteins | 1 | 2014 | 20 | 0.030 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2005 | 8 | 0.030 |
Why?
|
| Nuclear Proteins | 2 | 2005 | 11 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 2005 | 13 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2014 | 70 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2005 | 15 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2005 | 9 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 210 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2013 | 17 | 0.030 |
Why?
|
| Phylogeny | 1 | 2013 | 14 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2013 | 37 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 20 | 0.030 |
Why?
|
| Family Health | 2 | 2003 | 44 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 25 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2013 | 109 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2014 | 250 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2013 | 124 | 0.020 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2002 | 3 | 0.020 |
Why?
|
| Standard of Care | 1 | 2011 | 7 | 0.020 |
Why?
|
| Alcoholism | 1 | 1994 | 348 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2013 | 273 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 697 | 0.020 |
Why?
|
| Iron, Dietary | 1 | 2008 | 7 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 6 | 0.020 |
Why?
|
| Geography | 1 | 2008 | 39 | 0.020 |
Why?
|
| Epidemiologic Research Design | 1 | 2008 | 18 | 0.020 |
Why?
|
| beta Carotene | 1 | 2008 | 17 | 0.020 |
Why?
|
| Vitamin E | 1 | 2008 | 20 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 19 | 0.020 |
Why?
|
| Hemochromatosis Protein | 1 | 2008 | 7 | 0.020 |
Why?
|
| Homozygote | 1 | 2008 | 13 | 0.020 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1988 | 1 | 0.020 |
Why?
|
| Cicatrix | 1 | 1988 | 2 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 434 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2008 | 23 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2008 | 6 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2008 | 13 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 21 | 0.020 |
Why?
|
| Family Practice | 1 | 1988 | 44 | 0.020 |
Why?
|
| Morbidity | 1 | 2008 | 59 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2007 | 8 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 13 | 0.020 |
Why?
|
| Sulfonylurea Compounds | 1 | 2007 | 25 | 0.020 |
Why?
|
| Internship and Residency | 1 | 1988 | 45 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2007 | 33 | 0.020 |
Why?
|
| S-Adenosylmethionine | 1 | 2007 | 1 | 0.020 |
Why?
|
| Thigh | 1 | 2007 | 11 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2007 | 9 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 23 | 0.020 |
Why?
|
| Metformin | 1 | 2007 | 57 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2007 | 16 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2007 | 21 | 0.020 |
Why?
|
| Photosynthesis | 1 | 2006 | 1 | 0.020 |
Why?
|
| Plant Proteins | 1 | 2006 | 1 | 0.020 |
Why?
|
| Sulfites | 1 | 2006 | 1 | 0.020 |
Why?
|
| Sulfuric Acids | 1 | 2006 | 1 | 0.020 |
Why?
|
| Nitric Acid | 1 | 2006 | 1 | 0.020 |
Why?
|
| Copper Sulfate | 1 | 2006 | 1 | 0.020 |
Why?
|
| Photosystem II Protein Complex | 1 | 2006 | 1 | 0.020 |
Why?
|
| Fluorescence | 1 | 2006 | 2 | 0.020 |
Why?
|
| Ecosystem | 1 | 2006 | 3 | 0.020 |
Why?
|
| Light | 1 | 2006 | 3 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Muscle Relaxation | 1 | 2006 | 3 | 0.020 |
Why?
|
| Xanthines | 1 | 2006 | 6 | 0.020 |
Why?
|
| Nitrates | 1 | 2006 | 8 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 630 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2006 | 10 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2006 | 33 | 0.020 |
Why?
|
| Counseling | 1 | 1988 | 189 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 2006 | 14 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2006 | 29 | 0.020 |
Why?
|
| Washington | 1 | 2007 | 382 | 0.020 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2006 | 85 | 0.020 |
Why?
|
| North Carolina | 1 | 2005 | 33 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 379 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2004 | 2 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2004 | 2 | 0.020 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2004 | 3 | 0.020 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2004 | 10 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2004 | 5 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 13 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 2004 | 44 | 0.010 |
Why?
|
| Random Allocation | 1 | 2004 | 37 | 0.010 |
Why?
|
| Arizona | 1 | 1984 | 5 | 0.010 |
Why?
|
| Family | 1 | 2005 | 111 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 190 | 0.010 |
Why?
|
| Cost Control | 1 | 1984 | 21 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 50 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 114 | 0.010 |
Why?
|
| Endoscopy, Digestive System | 1 | 2002 | 10 | 0.010 |
Why?
|
| Age of Onset | 1 | 2002 | 79 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2002 | 69 | 0.010 |
Why?
|
| Managed Care Programs | 1 | 2003 | 325 | 0.010 |
Why?
|
| Proteins | 1 | 2001 | 16 | 0.010 |
Why?
|
| Maryland | 1 | 2000 | 16 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2000 | 27 | 0.010 |
Why?
|
| Sick Leave | 1 | 2000 | 8 | 0.010 |
Why?
|
| Atherectomy, Coronary | 1 | 2000 | 1 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 2000 | 4 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2000 | 10 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2000 | 25 | 0.010 |
Why?
|
| Reoperation | 1 | 2000 | 30 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2000 | 21 | 0.010 |
Why?
|
| Panic | 1 | 1999 | 1 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2000 | 77 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1999 | 125 | 0.010 |
Why?
|
| Recurrence | 1 | 2000 | 188 | 0.010 |
Why?
|
| Educational Status | 1 | 1999 | 200 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2000 | 188 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1988 | 16 | 0.000 |
Why?
|
| Groin | 1 | 1988 | 3 | 0.000 |
Why?
|
| Stress, Psychological | 1 | 1988 | 141 | 0.000 |
Why?
|